These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 11739369)

  • 1. Allowing for uncertainty in economic evaluations: qualitative sensitivity analysis.
    Walker D; Fox-Rushby J
    Health Policy Plan; 2001 Dec; 16(4):435-43. PubMed ID: 11739369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sensitivity analysis in economic evaluation: an audit of NICE current practice and a review of its use and value in decision-making.
    Andronis L; Barton P; Bryan S
    Health Technol Assess; 2009 Jun; 13(29):iii, ix-xi, 1-61. PubMed ID: 19500484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Statistical approaches to handling uncertainty in health economic evaluation.
    Briggs AH
    Eur J Gastroenterol Hepatol; 2004 Jun; 16(6):551-61. PubMed ID: 15167156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimizing a portfolio of health care programs in the presence of uncertainty and constrained resources.
    Sendi P; Al MJ; Gafni A; Birch S
    Soc Sci Med; 2003 Dec; 57(11):2207-15. PubMed ID: 14512250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sensitivity analysis in economic evaluation: a review of published studies.
    Briggs A; Sculpher M
    Health Econ; 1995; 4(5):355-71. PubMed ID: 8563834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modelling in the economic evaluation of health care: selecting the appropriate approach.
    Barton P; Bryan S; Robinson S
    J Health Serv Res Policy; 2004 Apr; 9(2):110-8. PubMed ID: 15099459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. At what price significance? The effect of price estimates on statistical inference in economic evaluation.
    Rittenhouse BE; Dulisse B; Stinnett AA
    Health Econ; 1999 May; 8(3):213-9. PubMed ID: 10348416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Common methodological flaws in economic evaluations.
    Drummond M; Sculpher M
    Med Care; 2005 Jul; 43(7 Suppl):5-14. PubMed ID: 16056003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Do health-care decision makers find economic evaluations useful? The findings of focus group research in UK health authorities.
    Hoffmann C; Stoykova BA; Nixon J; Glanville JM; Misso K; Drummond MF
    Value Health; 2002; 5(2):71-8. PubMed ID: 11918822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Uncertainty and sensitivity analyses of a dynamic economic evaluation model for vaccination programs.
    Duintjer Tebbens RJ; Thompson KM; Hunink MG; Mazzuchi TA; Lewandowski D; Kurowicka D; Cooke RM
    Med Decis Making; 2008; 28(2):182-200. PubMed ID: 18349438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analytic approaches for the evaluation of costs.
    Glick HA; Polsky D
    Hepatology; 1999 Jun; 29(6 Suppl):18S-22S. PubMed ID: 10386078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Value for money in the health sector: the contribution of primary health care.
    Mills A; Drummond M
    Health Policy Plan; 1987 Jun; 2(2):107-28. PubMed ID: 10312103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of model, methodological, and parameter uncertainty in the economic analysis of vaccination programs.
    Brisson M; Edmunds WJ
    Med Decis Making; 2006; 26(5):434-46. PubMed ID: 16997923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methodological limitations of economic evaluations of antenatal screening.
    Petrou S
    Health Econ; 2001 Dec; 10(8):775-8. PubMed ID: 11747056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Variability of cost-effectiveness estimates for pharmaceuticals in Western Europe: lessons for inferring generalizability.
    Barbieri M; Drummond M; Willke R; Chancellor J; Jolain B; Towse A
    Value Health; 2005; 8(1):10-23. PubMed ID: 15841890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic evaluation in health: a thumb nail sketch.
    Kernick DP
    BMJ; 1998 May; 316(7145):1663-5. PubMed ID: 9603756
    [No Abstract]   [Full Text] [Related]  

  • 17. How has the impact of 'care pathway technologies' on service integration in stroke care been measured and what is the strength of the evidence to support their effectiveness in this respect?
    Allen D; Rixson L
    Int J Evid Based Healthc; 2008 Mar; 6(1):78-110. PubMed ID: 21631815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure.
    McKenna C; Burch J; Suekarran S; Walker S; Bakhai A; Witte K; Harden M; Wright K; Woolacott N; Lorgelly P; Fenwick L; Palmer S
    Health Technol Assess; 2010 May; 14(24):1-162. PubMed ID: 20492762
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.